Loading...
•
Mar 31, 2022
Vir Q1 2022 Earnings Report
Reported financial results for the first quarter ended March 31, 2022.
Key Takeaways
Vir Biotechnology reported $1.2 billion of sotrovimab collaboration revenue in the first quarter of 2022 and has over $2.5 billion in cash, cash equivalents, investments and collaboration receivables. The company shared encouraging initial data from its Phase 2 MARCH trial evaluating hepatitis B functional cure.
Recorded $1.2 billion of sotrovimab collaboration revenue in Q1 2022.
More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of Q1 2022.
Shared encouraging initial data from MARCH trial evaluating hepatitis B functional cure in April.
Multiple value drivers in COVID-19, hepatitis B, hepatitis D, HIV and influenza expected in 2022.
Revenue by Segment
Forward Guidance
Vir Biotechnology anticipates multiple data readouts from Phase 2 and 3 COVID-19 trials, Phase 2 hepatitis B functional cure combination trials, and Phase 1 HIV trial. The company also expects to initiate Phase 2 trials for hepatitis B, hepatitis D and influenza.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...